美單日新增近11萬宗新冠確診 密歇根州住院新冠病人一個月內升近半
美國新冠疫情見反彈跡象。據美國約翰霍普金斯大學統計,截至美國西岸時間午夜(本港時間下午4時),美國累計新冠確診47,420,139宗,單日新增109,124宗。累計死亡個案767,435宗,單日新增1,522宗。
《今日美國報》報道,美國有33個州份七天新增新冠確診個案上升,其中密歇根州感染率全國最高,過去七日每10萬人有近504宗確診。當地醫院亦受到壓力,新冠病人較上月增長近五成,由上月18日的2,097人升至週一(15日)的3,082人。當地部分醫院要暫停非緊急手術,並不接收轉院個案。
另外,美國藥廠Moderna向美國食品及藥物管理局申請緊急授權,以準許所有成年人接種該藥廠的新冠疫苗作爲第三劑疫苗。輝瑞及BioNTech研發的「復必泰」疫苗料於周內獲得有關批準。
以下爲美國過去八天每日新冠疫情統計:
日期│累計確診│單日新增確診│累計死亡│單日新增死亡
11月17日(三)│47,420,139宗│+109,124宗│767,435宗│+1,522宗
11月16日(二)│47,311,015宗│+ 89,368宗│765,913宗│+1,548宗
11月15日(一)│47,221,647宗│+147,567宗│764,365宗│+1,273宗
11月14日(日)│47,074,080宗│+ 22,650宗│763,092宗│+ 120宗
11月13日(六)│47,051,430宗│+ 60,093宗│762,972宗│+ 451宗
11月12日(五)│46,991,337宗│+138,541宗│762,521宗│+2,844宗
11月11日(四)│46,852,796宗│+ 60,715宗│759,677宗│+ 617宗
11月10日(三)│46,792,081宗│+ 97,290宗│759,060宗│+1,654宗
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.